美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Latigo Biotherapeutics Inc

22.00

-0.3700-1.65%

盤後：22.000.00000.00%19:30 EDT

成交量：23.41萬

成交額：520.98萬

市值：13.91億

市盈率：-1.11

高：25.00

開：22.62

低：21.42

收：22.37

52周最高：25.00

52周最低：17.22

股本：6,323.80萬

流通股本：3,023.14萬

量比：1.33

換手率：0.77%

股息：- -

股息率：- -

每股收益(TTM):-19.7441

每股收益(LYR):-20.1159

淨資產收益率：--

總資產收益率：--

市淨率：-5.51

市盈率(LYR):-1.09

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Latigo Biotherapeutics Inc

交易所：

NASDAQ

成立時間：

2018

員工人數：

- -

公司地址：

1300 Rancho Conejo Boulevard,Suite 305,Thousand Oaks,California,United States

官網：

http://www.latigobio.com

郵編：

91320

電話：

傳真：

- -

簡介：

Latigo Biotherapeutics, Inc.於2018年11月在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司，致力於開發創新的非阿片類鎮痛藥物，旨在抑制疼痛傳播而不會產生成癮風險。其管道主要集中在Nav1.8抑製劑，初步開發努力針對肌肉骨骼疼痛。該公司還計劃探索涉及疼痛傳遞的其他離子通道靶點，以建立最廣泛的疼痛療法管道之一。

董事

名稱

職位

Nima Farzan

Chief Executive Officer and Director and President

Timothy P. Walbert

Chairman of the Board and Director

Beth Seidenberg

Director

Deborah Palestrant

Director

James B. Tananbaum

Director

Kevin Raidy

Director

Sara Bonstein

Director

Todd N. Smith

Director

股東

名稱

職位

Nima Farzan

Chief Executive Officer and Director and President

Neha Krishnamohan

Chief Business Officer and Chief Financial Officer

Neil Singla

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/LTGO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LTGO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","market":"US","secType":"STK","nameCN":"Latigo Biotherapeutics Inc","latestPrice":22,"timestamp":1787601600000,"preClose":22.37,"halted":0,"volume":234072,"hourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:30 EDT","volume":42,"amount":914.45,"timestamp":1787614207372,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016540008940545418,"floatShares":30231431,"shares":63238000,"eps":-19.74407,"marketStatus":"未開盤","change":-0.37,"latestTime":"08-24 16:00:00 EDT","open":22.62,"high":25,"low":21.42,"amount":5209781.4666,"amplitude":0.160036,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-19.74407,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":22.37,"preHourTrading":{"tag":"盘前","latestPrice":22.7,"preClose":22.37,"latestTime":"09:27 EDT","volume":2,"amount":45.370002,"timestamp":1787578020045,"change":0.33,"changeRate":0.014752,"amplitude":0.001341},"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:30 EDT","volume":42,"amount":914.45,"timestamp":1787614207372,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.325914},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","floatShares":30231431,"roa":"--","roe":"--","lyrEps":-20.11587,"volumeRatio":1.325914,"shares":63238000,"dividePrice":0,"high":25,"amplitude":0.160036,"preClose":22.37,"low":21.42,"week52Low":17.2201,"pbRate":"-5.51","week52High":25,"institutionHeld":0,"latestPrice":22,"eps":-19.74407,"divideRate":0,"volume":234072,"delay":0,"ttmEps":-19.74407,"open":22.62,"prevYearClose":18,"prevWeekClose":22.37,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":19.3,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTGO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTGO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LTGO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LTGO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LTGO","date":"2026-08-21","current":-1.114259,"percent":0,"low":-12.172536,"twenty":-11.41033,"median":-11.020695,"eighty":-10.534363,"high":-10.257227,"avg":-11.062207,"sd":0.589939,"marketCap":1353293842},"quantilePoints":[{"date":"2026-08-07","current":-10.257227,"twenty":-10.257227,"median":-10.257227,"eighty":-10.257227,"marketCap":1140357438},{"date":"2026-08-14","current":-11.41033,"twenty":-11.020695,"median":-10.545739,"eighty":-10.380784,"marketCap":1268554881},{"date":"2026-08-21","current":-12.172536,"twenty":-11.41033,"median":-11.020695,"eighty":-10.534363,"marketCap":1353293842}],"updateTime":1787629585867},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":672821642,"yearFounded":2018,"address":"1300 Rancho Conejo Boulevard,Suite 305,Thousand Oaks,California,United States","zipCode":"91320","officePhone":"805 716 2927","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.latigobio.com","stockEarnings":[{"period":"1week","weight":0.1478},{"period":"1month","weight":0.2428},{"period":"ytd","weight":0.2428}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Latigo Biotherapeutics, Inc.於2018年11月在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司，致力於開發創新的非阿片類鎮痛藥物，旨在抑制疼痛傳播而不會產生成癮風險。其管道主要集中在Nav1.8抑製劑，初步開發努力針對肌肉骨骼疼痛。該公司還計劃探索涉及疼痛傳遞的其他離子通道靶點，以建立最廣泛的疼痛療法管道之一。","exchange":"NASDAQ","name":"Latigo Biotherapeutics Inc","nameEN":"Latigo Biotherapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LTGO\",market:\"US\",,,undefined,":{"directors":[{"name":"Nima Farzan","position":"Chief Executive Officer and Director and President"},{"name":"Timothy P. Walbert","position":"Chairman of the Board and Director"},{"name":"Beth Seidenberg","position":"Director"},{"name":"Deborah Palestrant","position":"Director"},{"name":"James B. Tananbaum","position":"Director"},{"name":"Kevin Raidy","position":"Director"},{"name":"Sara Bonstein","position":"Director"},{"name":"Todd N. Smith","position":"Director"}],"executives":[{"name":"Nima Farzan","position":"Chief Executive Officer and Director and President"},{"name":"Neha Krishnamohan","position":"Chief Business Officer and Chief Financial Officer"},{"name":"Neil Singla","position":"Chief Medical Officer"}]}}}